Announcement
Cipla Health Limited, the fast‑moving wellness goods (FMWG) arm of Cipla, issued a press release from Mumbai on 6 July 2026 announcing the launch of Omnigel Maxstrong, its newest offering in the pain‑relief segment.
Product Details
Omnigel Maxstrong is formulated with 2% diclofenac, an advanced concentration increasingly adopted across the industry for managing recurring muscle and joint discomfort. The brand claims a five‑times faster action and long‑lasting relief, positioning the product for individuals with active daily routines that frequently trigger pain.
Formats and Availability
The new variant will be marketed in two delivery formats: a gel (30 g) and a spray available in 35 g, 55 g, 75 g and 100 g containers, thereby broadening consumer choice across different usage preferences.
Packaging and Branding
Omnigel Maxstrong introduces the first sub‑brand under the Omnigel umbrella and features a new contemporary premium packaging design. While the visual identity is refreshed, it retains the brand’s signature red colour palette and core pain‑relief cues to maintain continuity with existing brand equity.
About Cipla Health Limited
Incorporated in 2015, Cipla Health Limited was created to spearhead the wellness wave in India. The company now manages a diverse portfolio of 20 brands, many of which rank No. 1 or No. 2 in their respective categories. The portfolio includes:
- Pain Care: Omnigel
- Smoking Cessation: Nicotex
- Oral Rehydration Solutions: Prolyte
- Medicated Ointments: Cipladine
- Cough & Cold: Cofsils, Naselin
- Multi‑Vitamins: Maxirich
- Weight Gain: Endura Mass
- Personal Care: Rivela Dermascience, Cetafresh, Tugain Essentials, Astaberry
The launch of Omnigel Maxstrong marks a strategic expansion of Cipla Health’s pain‑relief line and reinforces its commitment to delivering effective, consumer‑focused wellness solutions.